X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs VENUS REMEDIES - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD VENUS REMEDIES WYETH LTD/
VENUS REMEDIES
 
P/E (TTM) x 27.7 -693.1 - View Chart
P/BV x 5.3 0.2 2,638.9% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   VENUS REMEDIES
EQUITY SHARE DATA
    WYETH LTD
Mar-13
VENUS REMEDIES
Mar-16
WYETH LTD/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,044218 479.1%   
Low Rs81882 996.3%   
Sales per share (Unadj.) Rs298.6365.6 81.7%  
Earnings per share (Unadj.) Rs57.21.5 3,851.9%  
Cash flow per share (Unadj.) Rs58.437.9 154.0%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.5382.5 65.2%  
Shares outstanding (eoy) m22.7211.44 198.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.10.4 760.0%   
Avg P/E ratio x16.3101.0 16.1%  
P/CF ratio (eoy) x15.94.0 402.9%  
Price / Book Value ratio x3.70.4 951.6%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1571,717 1,232.5%   
No. of employees `0000.51.0 48.2%   
Total wages/salary Rs m400324 123.3%   
Avg. sales/employee Rs Th13,787.44,100.7 336.2%   
Avg. wages/employee Rs Th813.0318.0 255.6%   
Avg. net profit/employee Rs Th2,643.316.7 15,859.8%   
INCOME DATA
Net Sales Rs m6,7834,183 162.2%  
Other income Rs m35320 1,754.2%   
Total revenues Rs m7,1364,203 169.8%   
Gross profit Rs m1,617812 199.3%  
Depreciation Rs m27417 6.4%   
Interest Rs m6380 1.4%   
Profit before tax Rs m1,93835 5,520.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m63218 3,492.8%   
Profit after tax Rs m1,30117 7,650.0%  
Gross profit margin %23.819.4 122.9%  
Effective tax rate %32.651.6 63.3%   
Net profit margin %19.20.4 4,717.1%  
BALANCE SHEET DATA
Current assets Rs m6,9842,771 252.1%   
Current liabilities Rs m2,0561,931 106.4%   
Net working cap to sales %72.620.1 362.0%  
Current ratio x3.41.4 236.8%  
Inventory Days Days99125 79.4%  
Debtors Days Days2454 44.5%  
Net fixed assets Rs m2445,328 4.6%   
Share capital Rs m227114 198.6%   
"Free" reserves Rs m5,4414,177 130.3%   
Net worth Rs m5,6684,376 129.5%   
Long term debt Rs m251,911 1.3%   
Total assets Rs m7,9018,428 93.7%  
Interest coverage x353.31.1 32,343.6%   
Debt to equity ratio x00.4 1.0%  
Sales to assets ratio x0.90.5 173.0%   
Return on assets %16.54.7 351.1%  
Return on equity %22.90.4 5,906.5%  
Return on capital %34.06.6 515.9%  
Exports to sales %0.20-   
Imports to sales %36.320.5 177.1%   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465858 287.2%   
Fx inflow Rs m150-   
Fx outflow Rs m2,677858 311.9%   
Net fx Rs m-2,662-858 310.1%   
CASH FLOW
From Operations Rs m923469 196.9%  
From Investments Rs m31729 1,085.3%  
From Financial Activity Rs m-481-464 103.8%  
Net Cashflow Rs m75935 2,200.3%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.2 6,277.8%  
FIIs % 7.2 0.6 1,241.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 66.4 45.8%  
Shareholders   21,978 20,121 109.2%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS